BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 35004330)

  • 1. Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib
    Hu HT; Luo JP; Cao GS; Li Z; Jiang M; Guo CY; Yuan H; Yao QJ; Geng X; Park JH; Cheng HT; Jiang L; Ma JL; Zhao Y; Li HL
    Front Oncol; 2021; 11():806907. PubMed ID: 35004330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
    Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
    [No Abstract]   [Full Text] [Related]  

  • 3. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization combined with computed tomography-guided 125iodine implantation enhances survival in hepatocellular carcinoma patients with portal vein tumor thrombus.
    Hu HT; Luo JP; Li HL; Guo CY; Yao QJ; Geng X; Jiang L
    Oncotarget; 2017 Apr; 8(17):29258-29268. PubMed ID: 28418927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of endovascular implantation of a portal vein stent combined with iodine-125 seed-strips followed by transcatheter arterial chemoembolization with sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis.
    Li S; Li L; Li B; Wang W
    Br J Radiol; 2020 Aug; 93(1112):20190279. PubMed ID: 32464068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.
    Zhu K; Chen J; Lai L; Meng X; Zhou B; Huang W; Cai M; Shan H
    Radiology; 2014 Jul; 272(1):284-93. PubMed ID: 24708192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of TACE combined with sorafenib
    Zhao XH; Yuan H; Xia WL; Zhang LL; Li Z; Cao GS; Li HL; Fan WJ; Li HL; Guo CY; Yao QJ; Zhu WB; Hu HT
    Front Oncol; 2022; 12():977462. PubMed ID: 36276129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of portal vein stent insertion and endovascular iodine-125 seed-strip implantation, followed by transcatheter arterial chemoembolization with sorafenib for treatment of hepatocellular carcinoma-associated portal vein tumor thrombus.
    Li S; Li B; Li L; Xu F; Yang X; Wang W
    J Contemp Brachytherapy; 2021 Dec; 13(6):670-679. PubMed ID: 35079254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of transcatheter arterial chemoembolization combined with either
    Li Y; Li H; Hu H; Yuan H; Zhao Y
    J Cancer Res Ther; 2020; 16(7):1691-1697. PubMed ID: 33565518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study.
    Chen J; Lai L; Luo J; Wang H; Li M; Huang M
    BMC Cancer; 2022 Nov; 22(1):1242. PubMed ID: 36451104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study.
    Cao Y; Sun T; Guo X; Ouyang T; Kan X; Chen L; Liang B; Wang M; Zheng C
    Front Oncol; 2021; 11():673378. PubMed ID: 34414104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
    Zhang X; Wang K; Wang M; Yang G; Ye X; Wu M; Cheng S
    Oncotarget; 2017 Apr; 8(17):29416-29427. PubMed ID: 28177886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lin LW; Yan LY; Ke K; Yang WZ; Lin JQ; Huang N
    Brachytherapy; 2023; 22(6):858-871. PubMed ID: 37574351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study.
    Yuan J; Yin X; Tang B; Ma H; Zhang L; Li L; Chen R; Xie X; Ren Z
    Biomed Res Int; 2019; 2019():2141859. PubMed ID: 31467872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization.
    Zhang Y; Miao H; Xie W; Jiang S; Song Z; Huang G; Fan W; Wang Y; Li J; Chen Y
    Eur Radiol; 2021 Jan; 31(1):232-243. PubMed ID: 32728770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
    Fan W; Yuan G; Fan H; Li F; Wu Y; Zhao Y; Yao W; Wang Y; Xue M; Yang J; Li J
    Clin Ther; 2019 Aug; 41(8):1463-1476. PubMed ID: 31303279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Zou X; Xu Q; You R; Yin G
    Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoembolization Plus Radiotherapy Versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis.
    Chu HH; Kim JH; Shim JH; Yoon SM; Kim PH; Alrashidi I
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.